Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Aug 8, 2024 08:00AM
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 May 10, 2024 08:00AM
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights May 9, 2024 08:00AM
Edgewise Therapeutics (EWTX) Appoints Arlene Morris to its Board of Directors May 7, 2024 08:03AM
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors May 7, 2024 08:00AM
View Older Stories

May 6, 2024 08:00AM Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
Apr 23, 2024 08:02AM Edgewise Therapeutics Inc. (EWTX) Granted EU Orphan Drug Designations for Sevasemten
Apr 23, 2024 08:00AM Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
Apr 15, 2024 04:06PM Edgewise Therapeutics (EWTX) Announces Positive Two-Year Topline Results from ARCH Open Label Trial of Sevasemten in Adults with Becker Muscular Dystrophy
Apr 15, 2024 04:05PM Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Mar 28, 2024 08:00AM Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
Mar 27, 2024 08:00AM Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
Mar 5, 2024 08:00AM Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
Feb 28, 2024 08:00AM Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
Feb 22, 2024 08:00AM Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Feb 13, 2024 08:02AM Edgewise Therapeutics (EWTX) Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy
Feb 13, 2024 08:00AM Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
Jan 9, 2024 08:39AM Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 19, 2023 08:00AM Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Dec 18, 2023 08:00AM Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
Nov 30, 2023 08:06AM Edgewise Therapeutics Inc. (EWTX) Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
Nov 30, 2023 08:00AM Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
Nov 9, 2023 08:00AM Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Nov 8, 2023 08:00AM Edgewise Therapeutics to Present at Upcoming Investor Conferences
Nov 1, 2023 08:00AM Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
Oct 26, 2023 08:03AM Edgewise Therapeutics (EWTX) Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy
Oct 26, 2023 08:00AM Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)
Sep 27, 2023 08:00AM Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society
Sep 26, 2023 08:00AM Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)
Sep 14, 2023 08:00AM Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunct
Aug 10, 2023 08:00AM Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Jun 26, 2023 04:01PM Edgewise Therapeutics Inc. (EWTX) Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy
Jun 26, 2023 04:01PM Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
Jun 6, 2023 08:00AM Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
May 11, 2023 08:00AM Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 2, 2023 08:00AM Edgewise Therapeutics to Present at Upcoming Investor Conferences
Mar 30, 2023 04:01PM Edgewise Therapeutics Inc. (EWTX) Reports Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of DMD
Mar 30, 2023 04:01PM Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models
Mar 21, 2023 08:00AM Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
Mar 14, 2023 08:00AM Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
Mar 6, 2023 08:04AM Edgewise Therapeutics Inc. (EWTX) Appoints Jonathan C. Fox to its Board
Mar 6, 2023 08:00AM Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
Mar 1, 2023 08:00AM Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023
Feb 28, 2023 08:00AM Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology
Feb 23, 2023 08:00AM Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
Feb 7, 2023 08:00AM Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023
Jan 4, 2023 08:30AM Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
Dec 21, 2022 09:00AM Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023
Dec 20, 2022 09:04AM Edgewise Therapeutics (EWTX) Appoints Marc Semigran As Chief Development Officer
Dec 20, 2022 09:00AM Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
Nov 9, 2022 08:00AM Edgewise Therapeutics to Present at Upcoming Investor Conferences
Nov 3, 2022 08:00AM Edgewise Therapeutics Reports Third Quarter 2022 Financial Results
Oct 27, 2022 04:05PM Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Oct 13, 2022 04:30PM Edgewise Therapeutics Inc. (EWTX) Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy
Oct 13, 2022 04:30PM Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
View Older Stories